Bupropion: Difference between revisions
Elcatracho (talk | contribs) |
Elcatracho (talk | contribs) |
||
| (4 intermediate revisions by the same user not shown) | |||
| Line 11: | Line 11: | ||
==Pediatric Dosing== | ==Pediatric Dosing== | ||
''Safety/efficacy not established | ''Safety/efficacy not established | ||
==Special Populations== | ==Special Populations== | ||
| Line 23: | Line 23: | ||
*Use of MAOI, linezolid, or methylene blue concomitantly or within past 2 weeks | *Use of MAOI, linezolid, or methylene blue concomitantly or within past 2 weeks | ||
*Seizure disorder | *Seizure disorder | ||
*Condition which lowers seizure threshold (e.g. abrupt cessation of ETOH, benzos, or AEDs, anorexia/bulimia, electrolyte derangement) | *Condition which lowers seizure threshold (e.g. abrupt cessation of ETOH, [[Benzodiazepines|benzos]], or AEDs, [[Anorexia nervosa|anorexia]]/[[Bulimia nervosa|bulimia]], electrolyte derangement) | ||
==Adverse Reactions== | ==Adverse Reactions== | ||
| Line 50: | Line 50: | ||
*Exact therapeutic mechanism unknown. Weakly inhibits neuronal uptake of dopamine and norepinephrine | *Exact therapeutic mechanism unknown. Weakly inhibits neuronal uptake of dopamine and norepinephrine | ||
*Structurally belongs to the class of [[Synthetic Cathinones|synthetic cathinones]] | *Structurally belongs to the class of [[Synthetic Cathinones|synthetic cathinones]] | ||
**Due to structure, can cause false positive screen for amphetamine on UDS<ref>Casey ER, Scott MG, Tang S, Mullins ME. Frequency of false positive amphetamine screens due to bupropion using the Syva EMIT II immunoassay. J Med Toxicol. 2011;7(2):105-108. doi:10.1007/s13181-010-0131-5</ref> | |||
==Comments== | ==Comments== | ||
Latest revision as of 04:43, 22 February 2021
Administration
- Type: Antidepressant
- Dosage Forms: tablet, sustained-release tablet, extended-release tablet
- Dosage Strengths: tablet: 75, 100mg; sustained-release tablet (Wellbutrin SR): 100, 150, 200mg; extended-release tablet (Wellbutrin XL): 150, 300mg; extended-release tablet (Aplenzin): 174, 348, 522mg; extended-release tablet (Forfivo XL): 450mg; extended-release tablet (Zyban): 150mg
- Routes of Administration: PO
- Common Trade Names: Wellbutrin, Wellbutrin SR, Wellbutrin XL, Zyban, Forfivo XL, Budeprion SR, Aplenzin, Buproban
Adult Dosing
- Immediate release: 100-150mg PO 2-4 times daily
- Sustained release: 150mg PO 1-2 times daily
Pediatric Dosing
Safety/efficacy not established
Special Populations
- Pregnancy Rating: C
- Lactation risk: infant risk cannot be ruled out
- Renal dosing: dose reduction or avoidance recommended
- Hepatic dosing: dose reduction or avoidance recommended
Contraindications
- Allergy to class/drug
- Use of MAOI, linezolid, or methylene blue concomitantly or within past 2 weeks
- Seizure disorder
- Condition which lowers seizure threshold (e.g. abrupt cessation of ETOH, benzos, or AEDs, anorexia/bulimia, electrolyte derangement)
Adverse Reactions
Serious
- Seizure
- Cardiac dysrhythmia
- Angle-closure glaucoma
- Suicidal ideation, worsening depression, mania, psychosis
Common
- Insomnia
- Dizziness, tremor
- Headache
- Nausea, constipation
- Tachyarrhythmia (10.8% )
- Pruritus, rash, urticaria
- Arthralgia, myalgia
- Tinnitus
- Xerostomia, pharyngitis
Pharmacology
- Half-life: 14-33h
- Metabolism: Hepatic, CYP2B6
- Excretion: Mostly renal
Mechanism of Action
- Exact therapeutic mechanism unknown. Weakly inhibits neuronal uptake of dopamine and norepinephrine
- Structurally belongs to the class of synthetic cathinones
- Due to structure, can cause false positive screen for amphetamine on UDS[1]
Comments
See Also
References
- ↑ Casey ER, Scott MG, Tang S, Mullins ME. Frequency of false positive amphetamine screens due to bupropion using the Syva EMIT II immunoassay. J Med Toxicol. 2011;7(2):105-108. doi:10.1007/s13181-010-0131-5